CLINICAL TRIALS PROFILE FOR ANAFRANIL
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Anafranil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00018200 ↗ | Effect of Antidepressants on Back Pain | Completed | US Department of Veterans Affairs | Phase 2 | 1999-04-01 | The purpose of this study is to determine whether different types of antidepressant medicines relieve back pain that has lasted at least six months on a daily basis. Study participants will be assigned to treatment with either a antidepressant acting on the serotonin system in the brain (fluoxetine), one acting on the noradrenaline system (desipramine, or to a control medication not expected to relieve pain (benztropine). Each participant will be seen at least nine times during their 12 weeks on medication. This is a phase 2/3, outpatient study. |
| NCT00018200 ↗ | Effect of Antidepressants on Back Pain | Completed | VA Office of Research and Development | Phase 2 | 1999-04-01 | The purpose of this study is to determine whether different types of antidepressant medicines relieve back pain that has lasted at least six months on a daily basis. Study participants will be assigned to treatment with either a antidepressant acting on the serotonin system in the brain (fluoxetine), one acting on the noradrenaline system (desipramine, or to a control medication not expected to relieve pain (benztropine). Each participant will be seen at least nine times during their 12 weeks on medication. This is a phase 2/3, outpatient study. |
| NCT00466609 ↗ | Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment | Completed | Conselho Nacional de Desenvolvimento Científico e Tecnológico | Phase 4 | 2007-05-01 | This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for obsessive compulsive disorder patients non-respondent to first line pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the association of fluoxetine with clomipramine. |
| NCT00466609 ↗ | Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment | Completed | Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 | 2007-05-01 | This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for obsessive compulsive disorder patients non-respondent to first line pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the association of fluoxetine with clomipramine. |
| NCT00466609 ↗ | Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment | Completed | Novartis | Phase 4 | 2007-05-01 | This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for obsessive compulsive disorder patients non-respondent to first line pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the association of fluoxetine with clomipramine. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Anafranil
Condition Name
Clinical Trial Locations for Anafranil
Trials by Country
Clinical Trial Progress for Anafranil
Clinical Trial Phase
Clinical Trial Sponsors for Anafranil
Sponsor Name
